Anti-scale composition for vapor space applications

By using a combination inhibitor of hydroxylamine, phenylenediamine, and benzoquinone or naphthoquinone, the problem of monomer polymerization in the vapor space of the distillation column was solved, thereby improving the safety and stability of the equipment.

CN118973999APending Publication Date: 2024-11-15ECOLAB USA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031775.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-01
Filing Date
2023-03-28
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing polymerization inhibitors cannot effectively suppress the spontaneous or peroxide-induced polymerization of olefinic unsaturated monomers in the vapor space of a distillation column, leading to equipment corrosion and safety hazards. Conventional inhibitors cannot reach the vapor space.

Method used

A composition containing hydroxylamine, phenylenediamine, and benzoquinone or naphthoquinone is used as an inhibitor. It is added to the monomer to inhibit polymerization. The concentration and molar ratio of each component in the composition can be adjusted to optimize the inhibitory effect.

Benefits of technology

It effectively inhibits monomer polymerization in the vapor space region, reduces equipment corrosion and safety risks, and improves the safety and stability of the process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973999A_ABST
    Figure CN118973999A_ABST
Patent Text Reader

Abstract

A polymerization inhibitor composition is provided. The polymerization inhibitor compositions comprise at least: a first inhibitor compound comprising a hydroxylamine; a second inhibitor, wherein the second inhibitor comprises phenylenediamine; and a third inhibitor, wherein the third inhibitor comprises benzoquinone or naphthoquinone. Methods of inhibiting polymerization of monomers using the compositions of the present disclosure are also provided. The methods of inhibiting polymerization of monomers include the step of adding a composition of the present disclosure to the monomer. In some cases, the monomer is an ethylenically unsaturated monomer. Such ethylenically unsaturated monomers include, but are not limited to, vinyl acetate, acrylonitrile, acrylates, methacrylates, 1, 3-butadiene, styrene, isoprene, (meth) acrylic acid, and combinations thereof. Methods of making the polymerization inhibitors and compositions of the present disclosure are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure generally relates to compositions comprising a blend of polymerization inhibitors and methods of using the compositions to inhibit unwanted polymerization in vapor space regions. More specifically, the present disclosure relates to compositions comprising at least one hydroxylamine compound having a stable nitroxide radical, a quinone, and a phenylenediamine, which compositions can be used to inhibit the polymerization of ethylenically unsaturated monomers. Background Art

[0002] Ethylenically unsaturated monomers are typically manufactured in a three-stage process consisting of (i) reaction, (ii) recovery, and (iii) purification. Distillation operations at high temperatures typically involve recovery and purification stages. The process includes fractionation of the monomers. At the top of the distillation tower, the purified monomer vapors are condensed into a liquid pool and then transferred to a storage facility. Some of the condensed monomer stream flows down the tower. In the vapor space region of the distillation tower, the liquid monomer pool may generate spontaneous or peroxide-initiated free radicals. Current polymer inhibitor technology is limited to the liquid stream at the bottom of the process tower. Inhibitors are typically non-volatile, so they are confined to the bottom of the distillation tower, and no inhibitor reaches the highly reactive monomer pool in the vapor space portion. For conventional inhibitors, the collected monomers are not treated to reduce unwanted polymerization. Therefore, reactive monomers are undesirably polymerized by free radical polymerization, particularly at elevated temperatures or when in contact with rust on the surface of process equipment such as distillation tower plates.

[0003] The polymerization is particularly vigorous in the presence of polymerization initiators such as organic peroxides, which are commonly found in recycle streams previously exposed to atmospheric oxygen. Conventional polymerization inhibitors such as 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (HTEMPO) and 4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl (OTEMPO) are generally effective. The premature polymerization of these monomers is usually controlled by metering the polymerization inhibitor directly into the liquid hydrocarbon stream to reduce the premature polymerization of the monomers. However, these polymerization inhibitors (HTEMPO and OTEMPO) are not volatile. In the art, the process is accelerated when the liquid monomer condenses on the trays, which are much higher than the bulk liquid treated with non-volatile polymerization inhibitors. The problem becomes very serious if the trays are rusted or when there is residual polymer in cracks and corners. Equally important, due to the Norris-Trommsdorf effect, pre-existing polymers in equipment cracks, dead legs and liquid monomer retention pools can lead to rapid accumulation of fouling polymers. Growing polymer fouling can cause mechanical damage due to accelerated polymerization and can release large amounts of heat, which can lead to fire or explosion. Complete inhibition of tray corrosion or complete removal of polymer from hard-to-reach locations in purification columns means that it is difficult to prevent unwanted polymerization in the vapor space. In this regard, there is an urgent need for effective anti-polymerization agents in the vapor space section of distillation columns. Summary of the invention

[0004] A composition for inhibiting monomer polymerization is provided, which comprises: a first inhibitor compound, which comprises hydroxylamine; a second inhibitor compound, which comprises phenylenediamine; and a third inhibitor compound, which comprises benzoquinone or naphthoquinone.

[0005] In some aspects, the first inhibitor compound has Formula (II):

[0006]

[0007] Where R2 is C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl, C1-C 22 Cycloalkyl, aryl, -C1-C 22 Alkylene, -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C1-C 22alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0008] In some aspects, R2 is -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C1-C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0009] In some aspects, the first inhibitor is selected from the group consisting of: 2,2,6,6-tetramethylpiperidin-1,4-diol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-Heptyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-Octyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-Nonyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-Decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-Undecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-Dodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-Tridecyloxy-2,2,6,6-tetramethylpiperidin- 1-ol; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol piperidin-1-ol; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-ol; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-ol; 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-ol; and any combination thereof.

[0010] In some aspects, the first inhibitor is a compound of Formula IIa:

[0011]

[0012] Where R4 is H, C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl, C1-C 22 Cycloalkyl, aryl, -C1-C 22 Alkylene, -C(O)(C1-C 22 Alkyl), -C(O)(C1-C22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C1-C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0013] In some aspects, the first inhibitor is selected from the group consisting of 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl acetate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl propionate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl ester, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl stearate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl benzoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl behenate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate, or any combination thereof.

[0014] In some aspects, the second inhibitor compound is a phenylenediamine of Formula (IV) or Formula (V):

[0015]

[0016] Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally replaced by one or more C1-C 22 Alkyl or aryl substituted.

[0017] In some aspects, the second inhibitor is selected from the group consisting of: 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diethyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, N,N′-diphenyl-1,4-phenylenediamine, and any combination thereof.

[0018] In some aspects, the third inhibitor compound is a benzoquinone of Formula (VI) or Formula (VII):

[0019]

[0020] Wherein X3, X4, X5 and X6 are independently H, Cl-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl or aryl substituted.

[0021] In some aspects, the third inhibitor compound is a naphthoquinone of Formula (VII) or Formula (VIII):

[0022]

[0023] Wherein X5 and X6 are independently H, C1-C 22 Alkyl, aryl, wherein the alkyl and aryl are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

[0024] In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 80 wt %, and the second inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 50 wt %.

[0025] In some aspects, the composition further comprises an organic solvent.

[0026] In some aspects, the composition further comprises an ethylenically unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid, and any combination thereof.

[0027] A method for inhibiting polymerization of a monomer is provided. The method comprises adding a composition as described herein to the monomer.

[0028] In some aspects, the monomers are provided in solution.

[0029] In some aspects, the solution further comprises one or more additional components selected from the group consisting of an acid, an organic solvent, and water.

[0030] In some aspects, the monomer is an ethylenically unsaturated monomer.

[0031] In some aspects, the composition is added to the monomer such that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

[0032] In some aspects, the composition is added to the monomer such that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

[0033] In some aspects, the monomer is selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid, and any combination thereof.

[0034] The above has been a fairly extensive overview of the features and technical advantages of the present disclosure so that the following specific description may be better understood. Other features and advantages of the present disclosure will be described below, which constitute the subject matter of the claims of this application. It will be appreciated by those skilled in the art that the disclosed concepts and specific aspects may be readily used as a basis for modifying or designing other aspects for achieving the same purpose of the present disclosure. It will also be appreciated by those skilled in the art that such disclosure of equivalent aspects does not depart from the spirit and scope of the present disclosure as described in the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Specific embodiments of the present invention are described below in detail with reference to the accompanying drawings.

[0036] Figure 1 A kinetic curve is shown which illustrates the effectiveness of the combination of 4-acetate TEMPO and N,N′-di-sec-butyl-1,4-phenylenediamine as an anti-polymerization agent compared to the performance of a combination of N,N′-di-sec-butyl-1,4-phenylenediamine and 2,6-di-tert-butylphenol at a 25 ppm dose in styrene polymerization using a static process at about 135°C. DETAILED DESCRIPTION

[0037] Various aspects of the present disclosure are described below. The relationship and function of various aspects of the elements can be better understood by reference to the following detailed description. However, various aspects are not limited to those explicitly described herein, and it should be understood that in some cases, details that are unnecessary for understanding various aspects disclosed herein, such as, for example, conventional synthesis and / or preparation, may have been omitted.

[0038] The present disclosure relates to compositions including a blend of polymerization inhibitors and methods of using the same to inhibit polymerization of ethylenically unsaturated monomers.The polymerization inhibitor compositions of the present disclosure comprise hydroxylamine, phenylenediamine, and benzoquinone or naphthoquinone.

[0039] In the presence of polymerizable monomers, a "polymerization inhibitor" inhibits the formation of polymers from these monomers during the induction time. After the induction time has elapsed, polymer formation occurs at substantially the same rate as in the absence of the polymerization inhibitor.

[0040] Polymerization inhibitors and polymerization retarders are generally considered "anti-polymerization agents," which are compounds that can inhibit or reduce the formation of polymers from one or more free radically polymerizable compounds.

[0041] The term "fouling" refers to the formation of polymers, prepolymers, oligomers and / or other materials that are insoluble in the stream and / or precipitate out of the stream and deposit on the equipment under the operating conditions of the equipment. Subsequently, the inhibitor, retarder and amine stabilizer components and compositions of the present disclosure may be referred to as "antifoulants" because they inhibit or reduce such formation.

[0042] Compositions of the present disclosure

[0043] The present disclosure relates to a composition for inhibiting the polymerization of a monomer, wherein the composition comprises: a first inhibitor compound, the first inhibitor compound comprising hydroxylamine; a second inhibitor compound, the second inhibitor compound comprising phenylenediamine; and a third inhibitor compound, the third inhibitor compound comprising benzoquinone or naphthoquinone. In some aspects, the composition is used to inhibit the polymerization of a monomer, wherein the monomer is an ethylenically unsaturated monomer. For example, the composition of the present disclosure can be used to inhibit the polymerization of an ethylenically unsaturated monomer, the ethylenically unsaturated monomer including but not limited to vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, (meth)acrylic acid, and combinations thereof.

[0044] In some aspects, the first inhibitor compound has Formula (II):

[0045]

[0046] Wherein R2 is selected from H, C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl, C1-C 22 Cycloalkyl, aryl, -C1-C 22 Alkylene, -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) and -C(O)(C1-C 22alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0047] The term "aryl" refers to monocyclic, bicyclic (fused) and tricyclic (fused or spiro) hydrocarbon ring systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring carbon atoms. The term "aryl" can be used interchangeably with the term "aryl ring".

[0048] In certain aspects, R2 is -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) and -C(O)(C1-C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0049] In some aspects, R2 is H. In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 Cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is aryl, wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C1-C 22 Alkylene, wherein the alkylene is optionally substituted by aryl, the aryl is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(C1-C 22In some aspects, R2 is -C(O)(C1-C 12 In some aspects, R2 is -C(O)(C1-C6 alkyl). In some aspects, R2 is -C(O)(methyl). In some aspects, R2 is -C(O)(ethyl). In some aspects, R2 is -C(O)(propyl). In some aspects, R2 is -C(O)(butyl). In some aspects, R2 is -C(O)(C1-C6 alkyl). 22 In some aspects, R2 is -C(O)(C1-C 22 In some aspects, R2 is -C(O)(C1-C 22 cycloalkyl), wherein the cycloalkyl is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(aryl), wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(C1-C 22 alkylene), wherein the alkylene is optionally substituted by an aryl group, the aryl group is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0050] In some aspects, the compound of formula (II) is 2,2,6,6-tetramethylpiperidin-1,4-diol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1 -ol; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-tridecyloxy-2,2,6,6-tetramethylpiperidin -1-ol; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6 ,6-tetramethylpiperidin-1-ol; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-ol; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-ol; or 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-ol.

[0051] In some aspects, the compositions of the present disclosure comprise compounds of formula (I) and (II), respectively, wherein R1 and R2 are the same. For example, in some aspects, the compositions of the present disclosure comprise compounds of formula (I) and (II), respectively, wherein R1 and R2 are each independently -C(O)(C1-C 22 In certain aspects, the compositions of the present disclosure comprise a first inhibitor compound and a second inhibitor compound of formula (I) and (II), respectively, wherein R1 and R2 are different.

[0052] In some aspects, the second inhibitor compound having a hydroxylamine is selected from the group consisting of:

[0053]

[0054] In some aspects, the second inhibitor compound having a hydroxylamine is:

[0055]

[0056] 4-Acetoxy-2,2,6,6-tetramethylpiperidin-1-ol.

[0057] In some aspects, the second inhibitor compound having a hydroxylamine is:

[0058]

[0059] 4-Propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol.

[0060] In some aspects, the second inhibitor compound having a hydroxylamine is:

[0061]

[0062] 4-Butoxy-2,2,6,6-tetramethylpiperidin-1-ol.

[0063] In some aspects, the second inhibitor compound having a hydroxylamine is:

[0064]

[0065] 4-Pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol.

[0066] The compounds of formula (II) with hydroxylamine disclosed in the present invention have advantages over the corresponding nitrogen oxides (compounds of formula (I)), such as the ability to provide additional polymerization inhibition, which will be explained more fully below. The general synthetic route of hydroxylamine to produce nitrogen oxides is to reduce its corresponding nitrogen oxide with a reducing agent as follows:

[0067]

[0068] Hydroxylamines of nitroxides have the potential to provide additional polymerization inhibition compared to the corresponding nitroxides in the presence of carbon-centered and oxygen-centered free radical initiators. This is explained as follows:

[0069]

[0070] Due to its weak NO-H bond in the compound, the hydroxylamine of nitrogen oxide is an excellent hydrogen donor, so it is an effective antioxidant. As an antioxidant, the hydroxylamine of nitroxide free radical easily reacts with oxygen-centered free radicals (such as peroxide free radicals), and it is converted into its corresponding nitroxide free radical. Nitrogen oxides are generally considered to be the most effective inhibitors because they have excellent inhibition ability by removing carbon-centered free radicals at a rate that almost controls diffusion. This rate is several orders of magnitude faster than phenolic compounds. However, their kinetic superiority is not always favorable. For example, when oxygen-centered free radicals exist as the main free radicals, it may lose its superiority. Another problem related to nitrogen oxides is its consumption by non-inhibition and undesirable reactions with process stream components or other inhibitor additives. Therefore, high nitrogen oxide inhibitor dosages are usually required for a given inhibition efficacy, making their use economically unattractive or even unfeasible.

[0071] In essence, when both oxygen-centered free radicals and carbon-centered free radicals are present, each hydroxylamine of the nitroxide is equivalent to a hydrogen donor plus a nitroxide anti-polymerizer, which is an attractive motivation provided by the hydroxylamine of the nitroxide. That is, one hydroxylamine of the nitroxide can eliminate one oxygen-centered free radical and one carbon-centered free radical, while the nitroxide can only eliminate the carbon-centered free radical.

[0072] In some aspects, the first inhibitor is a compound of Formula IIa:

[0073]

[0074] Where R4 is H, C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl, C1-C 22 Cycloalkyl, aryl, -C1-C 22 Alkylene, -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C1-C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.

[0075] In some aspects, the first inhibitor is a compound of Formula III:

[0076]

[0077] wherein R3 is -O· or -OH; and R4 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally replaced by one or more C1-C 22 Alkyl or aryl substituted.

[0078] In some aspects, R3 is -O. In some aspects, R3 is -OH.

[0079] In some aspects of Formula (IIa) and (III), R4 is optionally replaced by one or more C1-C 22 Alkyl or aryl substituted C1-C 22 In some aspects of formula (IIa) and (III), R4 is optionally replaced by one or more C1-C 22 In some aspects of formula (IIa) and (III), R4 is optionally substituted with one or more C1-C5 alkyl groups. 22 In some aspects of formula (IIa) and (III), R4 is optionally substituted with one or more C1-C4 alkyl groups. 22 Alkyl or aryl substituted C1-C 10 In some aspects of formula (IIa) and (III), R4 is optionally replaced by one or more C1-C 22 In some aspects, R4 is optionally substituted with one or more C1-C8 alkyl groups. 22 In some aspects, R4 is methyl. In some aspects, R4 is propyl. In some aspects, R4 is butyl. In some aspects, R4 is C5 alkyl. In some aspects, R4 is C6 alkyl. In some aspects, R4 is C7 alkyl. In some aspects, R4 is C8 alkyl. In some aspects, R9 is C5 alkyl. In some aspects, R4 is C 10 In some aspects, R4 is C 22 In some aspects, R4 is C 21 In some aspects, R4 is C 11 In some aspects, R4 is benzyl.

[0080] Examples of compounds of formula (IIa) or (III) include, but are not limited to, 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2 , 6,6-tetramethylpiperidin-4-yl ester; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; or 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate.

[0081] In some aspects, the compound of formula (IIa) or (III) is 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; or 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate. In some aspects, the compound of formula (IIa) or (III) is 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate. In some aspects, the compound of formula (IIa) or (III) is 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate. In some aspects, the compound of formula (IIa) or (III) is 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate.

[0082] In some aspects, the second inhibitor compound is a phenylenediamine of Formula (IV) or Formula (V):

[0083]

[0084] Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally replaced by one or more C1-C 22 Alkyl or aryl substituted.

[0085] In some aspects, the second inhibitor compound is a phenylenediamine of formula (IV). In some aspects, the second inhibitor compound is a phenylenediamine of formula (V).

[0086] Examples of phenylenediamines include, but are not limited to, 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diethyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, and N,N′-diphenyl-1,4-phenylenediamine.

[0087] In some aspects, the phenylenediamine is N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diethyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, or N,N′-diphenyl-1,4-phenylenediamine.

[0088] In some aspects, the phenylenediamine is N,N'-di-sec-butyl-1,4-phenylenediamine.

[0089] In some aspects, the phenylenediamine is N,N'-di-1,4-dimethylpentyl-1,4-phenylenediamine.

[0090] In some aspects, the phenylenediamine is N,N'-diethyl-1,4-phenylenediamine.

[0091] In some aspects, the phenylenediamine is N-tert-butyl-N'-phenyl-1,4-phenylenediamine.

[0092] In some aspects, the phenylenediamine is N,N'-diphenyl-1,4-phenylenediamine.

[0093] In some aspects, the third inhibitor compound is a benzoquinone of Formula (VI) or Formula (VII):

[0094]

[0095] Wherein X3, X4, X5 and X6 are independently H, Cl-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl or aryl substituted.

[0096] In some aspects, the third inhibitor compound is a benzoquinone of formula (VI). In some aspects, the third inhibitor compound is a benzoquinone of formula (VII).

[0097] In some aspects, the third inhibitor compound is a naphthoquinone of Formula (VII) or Formula (VIII):

[0098]

[0099] Wherein X5 and X6 are independently H, C1-C 22 Alkyl, aryl, wherein the alkyl and aryl are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.

[0100] In some aspects, X5 and X6 are independently H or C1-C 22 alkyl.

[0101] In some aspects, X5 and X6 are independently H or C1-C 15 alkyl.

[0102] In some aspects, X5 and X6 are independently H or C1-C 10 alkyl.

[0103] In some aspects, X5 and X6 are independently H or C1-C5 alkyl.

[0104] In some aspects, the third inhibitor compound is a naphthoquinone of formula (VII). In some aspects, the third inhibitor compound is a naphthoquinone of formula (VIII).

[0105] In some aspects, X3, X4, X5 and X6 are independently H or Cl-C 22 In some aspects, at least one of X3, X4, X5 and X6 is C1-C 22 In some aspects, X3, X4 and X5 are H, and X6 is C1-C 22 In some aspects, X3, X4 and X5 are H, and X6 is C1-C 10 In some aspects, X3, X4 and X5 are H, and X6 is tert-butyl.

[0106] Examples of benzoquinones include, but are not limited to, 2-tert-butyl-1,4-benzoquinone, 2-tert-butyl-5-methylbenzoquinone, 2-sec-butyl-5-methylbenzoquinone, 2-n-butyl-5-methylbenzoquinone, 2-sec-butyl-5-methylbenzoquinone, 2-isopropyl-5-methylbenzoquinone, 2,5-di-sec-butylbenzoquinone, 2,5-di-tert-butylbenzoquinone, 2,5-diisopropylbenzoquinone, 2,6-di-sec-butylbenzoquinone, 2,6-di-tert-butylbenzoquinone, 2,6-diisopropylbenzoquinone, 2,6-dimethylbenzoquinone, 2,5-dimethylbenzoquinone, 2,6-diethylbenzoquinone, 2,5-diethylbenzoquinone, 2,6-dipropylbenzoquinone, 2,5-dipropylbenzoquinone, 2,6-di-n-butylbenzoquinone, 2,5-di-n-butylbenzoquinone, 2,6-di-tert-butylbenzoquinone, 2,6-diisopropylbenzoquinone, 2-n-pentylbenzoquinone, 2,6-di-n-pentylbenzoquinone, 2,6-di-n-pentylbenzoquinone, 2-n-hexylbenzoquinone, 2,6-dihexylbenzoquinone, 2,6-dihexylbenzoquinone, 2-n-heptylbenzoquinone, 2,6-diheptylbenzoquinone, 2,6-diheptylbenzoquinone, 2-n-octylbenzoquinone, 2,6-dioctylbenzoquinone, 2,6-dioctylbenzoquinone, 2-n-nonylbenzoquinone, 2,6-dinonylbenzoquinone, 2,6-dinonylbenzoquinone, 2-n-decylbenzoquinone, 2,6-didecylbenzoquinone, 2,6-didecylbenzoquinone, 2-n-undecylbenzoquinone, 2,6-heneicosylbenzoquinone, 2,6-heneicosylbenzoquinone, 2-n-dodecylbenzoquinone, 2,6-docosylbenzoquinone and 2,6-docosylbenzoquinone.

[0107] In some aspects, the benzoquinone is 2-tert-butyl-1,4-benzoquinone.

[0108] Examples of naphthoquinones include, but are not limited to, 1,4-naphthoquinone, 1,2-naphthoquinone, 1-methyl-1,4-naphthoquinone, 1-ethyl-1,4-naphthoquinone, 1-n-propyl-1,4-naphthoquinone, 1-isopropyl-1,4-naphthoquinone, 1-n-butyl-1,4-naphthoquinone, 1-sec-butyl-1,4-naphthoquinone, 1-tert-butyl-1,4-naphthoquinone, 1-methyl-1,2-naphthoquinone, 1-ethyl-1,2-naphthoquinone, 1-n-propyl-1,2-naphthoquinone, 1-isopropyl-1,2-naphthoquinone, 1-n-butyl-1,2-naphthoquinone, 1-sec-butyl-1,2-naphthoquinone, and 1-tert-butyl-1,2-naphthoquinone.

[0109] In some aspects, the composition consists essentially of a first inhibitor compound, a second inhibitor compound, and a third inhibitor compound. In other aspects, the composition consists of an organic solvent, a first inhibitor, a second inhibitor, and a third inhibitor compound. In some aspects, the composition does not include 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl.

[0110] In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 80% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 70% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 60% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 40% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 30% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 20% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 10% by weight.

[0111] For example, in some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, about 50 wt %, about 55 wt %, about 60 wt %, about 65 wt %, about 70 wt %, about 75 wt %, or about 80 wt %.

[0112] In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 50% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 40% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 30% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 20% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 10% by weight.

[0113] For example, in some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, or about 50 wt %.

[0114] In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 80% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 70% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 60% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 40% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 30% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 20% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 10% by weight.

[0115] For example, in some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, about 50 wt %, about 55 wt %, about 60 wt %, about 65 wt %, about 70 wt %, about 75 wt %, or about 80 wt %.

[0116] In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:100. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 90:1 to about 1:90. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 80:1 to about 1:80. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 70:1 to about 1:70. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 60:1 to about 1:60. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 50:1 to about 1:50. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 40:1 to about 1:40. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 30:1 to about 1:30. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 20:1 to about 1:20. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 10:1 to about 1: 10. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is about 1:1.

[0117] In some aspects, the composition further comprises one or more additional compounds selected from the group consisting of: 2,2,6,6-tetramethylpiperidin-1-oxyl; 2,2,6,6-tetramethylpiperidin-1-ol; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-oxo-2 , 2,6,6-tetramethylpiperidin-1-ol; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol; and bis((2,2,6,6-tetramethylpiperidin-1-oxyl)-4-yl)oxalate. In some aspects, the composition further comprises 2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition further comprises 2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition further comprises 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition further comprises 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes oxalic acid bis((2,2,6,6-tetramethylpiperidin-1-oxy)-4-yl) ester.

[0118] The composition can also optionally include one or more organic solvents. It will be appreciated by those of ordinary skill in the art that there are many organic solvents compatible with the composition of the present disclosure. For example, in some aspects, one or more organic solvents are selected from vinyl acetate, dimethyl phthalate, dimethyl formamide, toluene, xylene, high aromatic naphtha, acetonitrile, ethyl acetate, acetone, methylene chloride, tetrahydrofuran, hexane, dimethyl sulfoxide, N-methyl-2-pyrrolidone and combinations thereof. In some aspects, the composition also includes vinyl acetate. In some aspects, the composition also includes dimethyl phthalate. In some aspects, the composition also includes dimethyl formamide. In some aspects, the composition also includes toluene. In some aspects, the composition also includes xylene. In some aspects, the composition also includes high aromatic naphtha. In some aspects, the composition also includes acetonitrile.

[0119] In some aspects, the composition also includes one or more ethylenically unsaturated monomers. It will be appreciated by those of ordinary skill in the art that there are many ethylenically unsaturated monomers compatible with the compositions of the present disclosure. For example, in some aspects, one or more ethylenically unsaturated monomers are selected from vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, (meth) acrylic acid and combinations thereof. In some aspects, the composition also includes vinyl acetate. In some aspects, the composition also includes acrylonitrile. In some aspects, the composition also includes acrylate. In some aspects, the composition also includes methacrylate. In some aspects, the composition also includes 1,3-butadiene. In some aspects, the composition also includes styrene. In some aspects, the composition also includes isoprene. In some aspects, the composition also includes acrylic acid and (meth) acrylic acid.

[0120] Methods of using the compositions of the present disclosure

[0121] The present disclosure also relates to methods of inhibiting polymerization of monomers, comprising adding a composition of the present disclosure to the monomers. In some aspects, an effective amount of a composition of the present disclosure is added to the monomers, wherein an effective amount is any amount sufficient to inhibit polymerization of the monomers.

[0122] In some aspects, the monomer is an ethylenically unsaturated monomer. In some aspects, the monomer is an ethylenically unsaturated monomer selected from vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, (meth) acrylic acid and combinations thereof. In some aspects, the method disclosed herein can be used to inhibit the polymerization of vinyl acetate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylonitrile. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of methacrylate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of 1,3-butadiene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of styrene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of isoprene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of (meth) acrylic acid.

[0123] The composition of the present disclosure can be added to the fluid manually or automatically. The composition can also be added continuously and / or intermittently. Automatic addition can be accomplished by using a chemical dosing pump. The chemical dosing pump can be programmed to add a specific amount of the polymerization inhibitor composition or any component thereof to the fluid at certain time intervals. In optional aspects, the chemical dosing pump can be manually controlled to add a specific amount of the polymerization inhibitor composition or any component thereof to the fluid. Adding the currently disclosed polymerization inhibitor composition to the monomer will thus inhibit the polymerization of the monomer.

[0124] In some aspects, the monomer is provided as a pure liquid. In other aspects, the monomer is provided in a solution, hereinafter referred to as a "monomer solution".

[0125] In some aspects, the monomer solution further comprises one or more additional components selected from acids, organic solvents, water, and combinations thereof. For example, in some aspects, the monomer solution comprises one or more organic solvents selected from vinyl acetate, dimethyl phthalate, dimethylformamide, toluene, xylene, high aromatic naphtha, acetonitrile, ethyl acetate, acetone, methylene chloride, tetrahydrofuran, hexane, dimethyl sulfoxide, N-methyl-2-pyrrolidone, and combinations thereof.

[0126] In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 500 ppm.

[0127] In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 500 ppm.

[0128] In some aspects, the composition is added to the monomer so that the concentration of the third inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the third inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the third inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the third inhibitor compound is from about 0.1 ppm to about 500 ppm.

[0129] The methods of the present disclosure can be used to inhibit premature polymerization of monomers in manufacturing processes, particularly those conducted under acidic conditions. For example, the methods of the present disclosure can be used to prevent polymerization of acrylates, which can include but are not limited to acrylonitrile, acrylic acid, methacrylic acid and its esters, and vinyl acetate.

[0130] The methods of the present disclosure can also be used to prevent premature polymerization of styrene during the manufacturing and purification processes.

[0131] The method of the present disclosure can also be used in butadiene extraction process. This utility is derived from the equilibrium partition coefficient between the polar organic phase and the organic phase.

[0132] In some aspects, the compositions disclosed herein are used for distillation purification of olefins. For example, the composition can be added to a process stream before entering a distillation unit, or the composition can be added to a process stream in a distillation unit.

[0133] Example

[0134] Example 1 - Polymerization Inhibition Using N,N-Di-Sec-Butylphenylenediamine (PDA)

[0135] The ability of the compositions of the present disclosure to inhibit the polymerization of polystyrene was evaluated by the following protocol. Styrene was used as a reactive monomer for polymerization kinetics studies and screening of the proposed anti-polymer products. To prevent polymerization during storage and transportation, styrene was stabilized with tert-butylcatechol (TBC). For each experiment, the stabilizer was removed and freshly washed styrene was used immediately. Styrene was used as a reactive monomer for polymerization kinetics studies and screening of the proposed anti-polymer products. To prevent polymerization during storage and transportation, styrene was stabilized with TBC. For each experiment, the stabilizer was removed and freshly washed styrene was used immediately.

[0136] As a precaution, styrene that has been cleaned and stored overnight must be discarded, even under subzero refrigeration, because significant polymerization occurs during storage. TBC is removed using a chromatographic column using alumina. The alumina column is prepared on the day of a scheduled set of experiments.

[0137] About 300 mL of pure styrene treated with about 400 ppm N, N-di-sec-di-sec-butylphenylenediamine (prototype PDA) was charged into a 500 mL round-bottom flask. A thermocouple was inserted directly into the reaction solution, and the reaction temperature of the solution was set to 115 ° C. In order to prevent the reaction solution from being lost due to evaporation, the flask was equipped with a reflux device before being placed on the heating block. During the kinetic study, a stream of nitrogen flowed through the reaction solution under vigorous stirring through another port. When the solution temperature reached 115 ° C, it was the beginning of the study, or time zero. A sample of the reaction solution was taken out of the reactor and the solution was immediately diluted with toluene. The concentration of polystyrene in the diluted solution was analyzed using a proprietary program. From this time point on, samples were collected every 20 minutes, and the reaction solution was similarly diluted and analyzed for the concentration of polystyrene.

[0138] Example 2 - Polymerization Inhibition Using 4-AcetoxyTEMPOH

[0139] The polymerization reactor was charged with 300 mL of freshly purged styrene treated with 400 ppm 4-acetoxyTEMPOH. Reaction kinetics studies were performed as described in Example 1.

[0140] Example 3 - Polymerization Inhibition Using 2-tert-Butylbenzoquinone

[0141] Using the procedure in the above example, the anti-polymerization properties of 400 ppm 2-tert-butylbenzoquinone were investigated.

[0142] Example 4 - Polymerization Inhibition Using a Synergistic Combination of 2-tert-Butylbenzoquinone, 4-acetoxyTEMPOH and PDA

[0143] Freshly prepared 300 mL of styrene solution was treated with 52 ppm TBBQ, 174 ppm PDA and 174 ppm 4-acetoxyTEMPOH. The solution was transferred to a polymerization reactor and subsequently subjected to kinetic studies using the procedure in the previous examples.

[0144] The samples tested and the results are shown in Figure 1 and are summarized in Table 1 below.

[0145] Table 1. Percentage (w / w) concentration of polystyrene under anaerobic conditions .

[0146]

[0147] All compositions and methods disclosed and claimed herein can be prepared and performed according to the present disclosure without undue experimentation. Although the present invention can be embodied in many different forms, specific preferred embodiments of the present invention are described in detail herein. The present disclosure is an illustration of the principles of the present invention and is not intended to limit the present invention to the specific embodiments shown. In addition, unless explicitly stated to the contrary, the use of the term "one / kind" is intended to include "at least one / at least one" or "one or more / one or more". For example, "compound" is intended to include "at least one compound" or "one or more compounds".

[0148] Any range given in absolute terms or in approximate terms is intended to cover both, and any definition used herein is intended to be clarifying and not restrictive. Although the numerical ranges and parameters describing the broad scope of the present invention are approximate, the numerical values ​​described in the specific embodiments are reported as accurately as possible. However, any numerical value inherently contains certain errors caused by the standard deviation found in its corresponding experimental measurement. In addition, all ranges disclosed herein are understood to cover any and all subranges (including all fractional values ​​and overall values) contained therein.

[0149] Any composition disclosed herein may comprise, consist of, or consist essentially of any element, component, and / or ingredient disclosed herein, or any combination of two or more of the elements, components, or ingredients disclosed herein.

[0150] Any method disclosed herein may comprise, consist of, or consist essentially of any method step disclosed herein or any combination of two or more of the method steps disclosed herein.

[0151] The transitional phrase "comprising," which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional unrecited elements, components, ingredients, and / or method steps.

[0152] The transitional phrase "consisting of" excludes any element, component, ingredient and / or method step not specified in the claim.

[0153] The transition phrase "consisting essentially of" limits the scope of a claim to the specified elements, components, ingredients and / or steps, and those that do not materially affect the basic and novel characteristics of the claimed invention.

[0154] As used herein, the term "about" means that the recited value is within the standard deviation found in their respective testing measurements, and if those errors are not determinable, "about" may mean, for example, within 5% of the recited value.

[0155] In addition, the present invention encompasses any and all possible combinations of some or all of the various aspects described herein. It should also be understood that the various changes and modifications made to the current preferred aspects described herein are obvious to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention and without reducing its expected advantages. Therefore, the appended claims are intended to cover such changes and modifications.

Claims

1. A composition for inhibiting monomer polymerization, the composition comprising: a first inhibitor compound, the first inhibitor compound comprising hydroxylamine; a second inhibitor compound comprising a phenylenediamine; and A third inhibitor compound comprises benzoquinone or naphthoquinone.

2. The composition of claim 1, wherein the first inhibitor compound has formula (II): Where R 2 It is C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl, C 1 -C 22 Cycloalkyl, aryl, -C 1 -C 22 Alkylene, -C(O)(C 1 -C 22 alkyl), -C(O)(C 1 -C 22 alkenyl), -C(O)(C 1 -C 22 Alkynyl), -C(O)(C 1 -C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C 1 -C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl or aryl substitution.

3. The composition according to claim 1 or 2, wherein R 2 Yes -C(O)(C 1 -C 22 alkyl), -C(O)(C 1 -C 22 alkenyl), -C(O)(C 1 -C 22 Alkynyl), -C(O)(C 1 -C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C 1 -C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl or aryl substitution.

4. The composition of claim 1 or 2, wherein the first inhibitor is selected from the group consisting of: 2,2,6,6-tetramethylpiperidine-1,4-diol; 4-methoxy-2,2,6,6-tetramethylpiperidine-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidine-1-ol 4-propoxy-2,2,6,6-tetramethylpiperidine-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidine-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidine-1-ol; 4-hexyloxy -2,2,6,6-tetramethylpiperidin-1-ol 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-ol 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-ol 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol 4-tridecyloxy-2,2,6,6 -tetramethylpiperidin-1-ol; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6, 6-Tetramethylpiperidin-1-ol 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-ol 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-ol; 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-ol; and any combination thereof.

5. The composition of claim 1, wherein the first inhibitor is a compound of formula IIa: Where R 4 It is H, C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl, C 1 -C 22 Cycloalkyl, aryl, -C 1 -C 22 Alkylene, -C(O)(C 1 -C 22 alkyl), -C(O)(C 1 -C 22 alkenyl), -C(O)(C 1 -C 22 Alkynyl), -C(O)(C 1 -C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C 1 -C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted by one or more C 1 -C 22 Alkyl, C 1 -C 22 Alkenyl, C 1 -C 22 Alkynyl or aryl substitution.

6. The composition of claim 5, wherein the first inhibitor is selected from the group consisting of 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl acetate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl propionate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate, , 2,6,6-tetramethylpiperidin-4-yl ester, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl stearate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl benzoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl behenate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate, or any combination thereof.

7. The composition according to any one of claims 1 to 6, wherein the second inhibitor compound is a phenylenediamine of formula (IV) or formula (V): Where X 1 and X 2 Independently C 1 -C 22 alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C 1 -C 22 Alkyl or aryl substituted.

8. The composition of any one of claims 1 to 6, wherein the second inhibitor is selected from the group consisting of 1,2-phenylenediamine, 1,4-phenylenediamine, N,N'-dimethyl-p-phenylenediamine, N,N'-di-sec-butyl-1,4-phenylenediamine, N,N'-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N'-diethyl-1,4-phenylenediamine, N-tert-butyl-N'-phenyl-1,4-phenylenediamine, N,N'-diphenyl-1,4-phenylenediamine, and any combination thereof.

9. The composition according to any one of claims 1 to 8, wherein the third inhibitor compound is a benzoquinone of formula (VI) or formula (VII): Where X 3 , X 4 , X 5 and X 6 Independently H, C 1 -C 22 alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C 1 -C 22 Alkyl or aryl substituted.

10. The composition of any one of claims 1 to 8, wherein the third inhibitor compound is a naphthoquinone of formula (VII) or formula (VIII): Where X 5 and X 6 Independently H, C 1 -C 22 Alkyl, aryl, wherein the alkyl and aryl are optionally substituted by one or more C 1 -C 22 Alkyl or aryl substituted.

11. The composition of any one of claims 1 to 10, wherein the first inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 80 wt %, and the second inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 50 wt %.

12. The composition according to any one of claims 1 to 11, wherein the composition further comprises an organic solvent.

13. The composition of any one of claims 1 to 12, wherein the composition further comprises an ethylenically unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid, and any combination thereof.

14. A method for inhibiting monomer polymerization, the method include: The composition according to any one of claims 1 to 13 is added to the monomer.

15. The method of claim 14, wherein the monomer is provided in solution.

16. The method of claim 15, wherein the solution further comprises one or more additional components selected from the group consisting of an acid, an organic solvent, and water.

17. The method of any one of claims 14 to 16, wherein the monomer is an ethylenically unsaturated monomer.

18. The method of any one of claims 14 to 17, wherein the composition is added to the monomer such that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

19. The method of any one of claims 14 to 17, wherein the composition is added to the monomer such that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm.

20. The method of any one of claims 14 to 19, wherein the monomer is selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid, and any combination thereof.